Zevalin Y-90 is a targeted radioimmunotherapy drug used in the treatment of certain types of non-Hodgkin’s lymphoma. This medication combines the power of a monoclonal antibody with the radioactive isotope Yttrium-90 to specifically target and destroy cancerous B-cells in the body.

Zevalin Y-90 works by attaching itself to a protein called CD20, which is found on the surface of B-cells. Once attached, the radioactive Yttrium-90 emits radiation that directly targets and kills the cancerous cells while sparing healthy surrounding tissue. This targeted approach helps to minimize side effects and improve the overall effectiveness of the treatment.

Patients receiving Zevalin Y-90 may experience some common side effects such as fatigue, nausea, and low blood cell counts. It is important for patients to discuss any concerns or side effects with their healthcare provider to ensure proper management and support throughout treatment.

As with any medication, it is important for patients to follow their healthcare provider’s instructions carefully and attend all scheduled appointments for monitoring and follow-up. Zevalin Y-90 is typically administered in a specialized healthcare setting by trained professionals who are experienced in radioimmunotherapy.

Overall, Zevalin Y-90 has shown promising results in the treatment of non-Hodgkin’s lymphoma and offers a targeted approach to destroying cancerous cells while minimizing damage to healthy tissue. If you have been prescribed Zevalin Y-90 or are considering this treatment option, be sure to discuss any questions or concerns with your healthcare provider to determine if this medication is right for you.